Cancer News and Research

Latest Cancer News and Research

St. John’s wort may interfere with cancer-fighting drug’s ability to prevent relapse in leukemia patients

St. John’s wort, an herb thought to be a safe, natural remedy for mild depression, may interfere with a powerful cancer-fighting drug’s ability to prevent relapse in leukemia patients, a University of Florida pharmacy researcher will report March 27 at the annual meeting of the American Society for Clinical Pharmacology and Therapeutics.

26 Mar 2004

New patent to develop antibody therapies for cancer and other diseases

The University of Rochester Medical Center and Vaccinex, Inc. announced today the award of a key U.S. patent for a technology platform that can assist researchers in finding new treatments for cancer and other diseases. While the technology has many applications, one promising use is for the identification of certain proteins, called monoclonal antibodies, that are capable of seeking out and destroying harmful cells. Several companies have recently developed monoclonal antibodies as treatments for cancer, rheumatoid arthritis, and other conditions. Under an exclusive, worldwide license from the University of Rochester, Vaccinex is using the patented technology to discover and develop new monoclonal antibody therapies.

26 Mar 2004

Researchers have successfully grafted human breast tissue into the mammary glands of mice

The last few years have witnessed critical advances in breast cancer therapies. Still, the disease afflicts one in eight American women, and scientists have yet to develop a living model with which they can study the intricacies of human breast-tumor behavior.

26 Mar 2004

p53 protein peptide stops cancer in its tracks

Researchers have dreamed of thwarting cancer by using proteins that halt cell growth and kill the tumor. In theory, the approach should work. In practice, however, scientists have not had an easy time of getting tumor suppressor proteins into cells where they can block growth effectively.

26 Mar 2004

Oral chemotherapy agent Orathecin™ (rubitecan) capsules accepted by FDA for filing

SuperGen Inc. announced today that the Food and Drug Administration (FDA) has officially accepted the Orathecin™ (rubitecan) capsules’ New Drug Application (NDA) for filing. Orathecin, an investigational anticancer compound, is an oral chemotherapy agent that has been investigated as a treatment for pancreatic cancer patients who have failed at least one prior chemotherapy.

26 Mar 2004

New computerized tool to assist surgeons in planning cryosurgery

Carnegie Mellon University's Yoed Rabin is leading an interdisciplinary research team in developing a new computerized tool to assist surgeons in planning cryosurgery, now being used to freeze undesired tissues in prostate cancer patients.

26 Mar 2004

Pregnancies that end in miscarriage or abortion do not increase a woman's risk of developing breast cancer

A Study coordinated by Cancer Research UK scientists has shown that pregnancies that end in miscarriage or abortion do not increase a woman's risk of developing breast cancer later in life.

26 Mar 2004

Bionomics files novel angiogenesis genes patent

Bionomics Limited has announced that it had filed a further international patent application that covers 496 proprietary angiogenesis drug targets. The international patent application applies to genes that Bionomics has identified using advanced technologies such as microarray and bioinformatics analyses. These technologies have enabled Bionomics to identify novel angiogenesis genes that have not been identified by other companies or research groups.

26 Mar 2004

Joint Research Collaboration to Predict 3-D Protein Structures and Support Drug Discovery

IBM today announced that the University at Buffalo (UB) Center of Excellence in Bioinformatics, The State University of New York, will use IBM technologies and research expertise to study the structure and behavior of human proteins. The outcome of this research could lead to more targeted drugs to treat diseases such as cancer, Alzheimer's, AIDS and multiple sclerosis.

25 Mar 2004

Researchers turn off individual human genes to study their function

Researchers have produced vast libraries of short segments of ribonucleic acid (RNA) that can be used to turn off individual human and mouse genes to study their function. The libraries will be made widely available to laboratories studying human biology and disease. The researchers are optimistic that the libraries will become a powerful research tool for gene analysis and discovery.

25 Mar 2004

New Research Information on Tumor Necrosis Therapy

Researchers for Peregrine Pharmaceuticals presented today at the Strategic Research Institute’s Clinical-Stage Product Partnering Summit in La Jolla, CA a summary of clinical experience with Tumor Necrosis Therapy (TNT). The TNT technology is being developed in the U.S. and Europe by Peregrine under the trade name Cotara™. Over 200 patients have been treated with TNT world-wide and a TNT product has been approved to treat grade III or IV advanced lung cancer in the People’s Republic of China. A Cotara registration study for brain cancer has been approved by the U.S. Food and Drug Administration, and a Phase I colorectal cancer study is on-going at Stanford University Medical Center.

25 Mar 2004

iCAD issued with Fulcrum mammography film digitizer patent

iCAD, Inc., which designs, develops and markets Computer Aided Detection (CAD) imaging technology and systems for the early detection of breast cancer and other medical applications, today announced that the U.S. Patent and Trademark Office has issued the Company two patents for its Fulcrum mammography film digitizer and technology.

24 Mar 2004

Oregon Stem Cell Center Hunt for Human Disease Therapies

Oregon Health & Science University's fast-growing stem cell research program, which already has made significant strides in the hunt for human disease therapies, now has a place to call home.

23 Mar 2004

Carbon Dioxide may be used in medical implants

Carbon dioxide, an environmentally friendly solvent for dyeing and dry cleaning, may become a valuable new tool for making medical implants, according to a study at Ohio State University.

23 Mar 2004

Alcohol Consumption Decreases Risk of Heart Disease in Men

Cardiovascular disease, including heart disease and stroke, is the leading cause of death in the United States. To help combat this epidemic, studies throughout the United States pinpoint dietary guidelines to reduce risk including a recent release from the American Heart Association which stated that hypertensive patients should avoid alcoholic beverages.

23 Mar 2004

New computer program accurately estimates chance of developing breast cancer

CANCER Research UK scientists have devised a user-friendly computer program, called the IBIS risk evaluator, which can give the most accurate estimate yet of a woman's chance of developing breast cancer.

22 Mar 2004

Tiny Ribozyme package could be future treatment of Hepatitis B virus

Penn State College of Medicine researchers have developed a tiny package that searches for and destroys up to 80 percent of hepatitis B virus in the livers of mice.

22 Mar 2004

DNA repair enzymes to fight cancer

The body has a set of DNA repair enzymes that clean up damage to the genome, to reduce potential problems. Many commonly used cancer chemotherapies work by alkylating DNA. However, the DNA repair enzymes are just as capable of repairing this alkylation as if it were damage from any other source, and so they act to overcome the effects of the therapy, reducing its effectiveness.

22 Mar 2004

Clinical study - Diagnostic testing for epilepsy released

Bionomics Limited announced today the publication of its international clinical study involving patients with a form of epilepsy confined to early childhood in the scientific journal, Annals of Neurology. The publication details genes associated with a condition known as Benign Familial Neonatal Infantile Spasms (BFNIS), a condition in which infants experience seizures in the first few months of their life.

22 Mar 2004

Plasticiser Phthalates connected with rising infertility rates

Phthalates, largely used as plasticisers, have long been suspected in connection with rising infertility rates, particularly among men. These substances are quite common and are considered highly hazardous to human health because they disrupt the hormonal balance and impair reproduction and development. What has not been clear up to now is the amount of phthalates that enter the human body.

22 Mar 2004